NeurIPS 2025 - AI Research Engineer & Scientist at Abata Therapeutics

South San Francisco, California, United States

Abata Therapeutics Logo
Not SpecifiedCompensation
Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, AI, Drug DiscoveryIndustries

Requirements

  • AI Research Engineer
  • Bachelor's degree in Computer Science, Engineering, or related fields
  • Minimum of two years of industry experience in AI, machine learning, or related roles, with a track record of successfully implementing and deploying AI models in production environments
  • Proficiency in programming languages such as Python, and experience with relevant libraries, toolchain and frameworks for AI model development
  • Strong understanding of deep learning fundamentals, including neural network architectures, optimization techniques, and evaluation metrics
  • Publication track record at conferences such as NeurIPS, ICML, ICLR, etc
  • Experience applying LLM + RAG to biomedical or healthcare use cases
  • Knowledge of multimodal model development (text, omics, imaging)
  • Familiarity with drug discovery processes, computational chemistry, or bioinformatics is desirable
  • Excellent problem-solving skills, with a keen eye for detail and a passion for tackling complex challenges in healthcare
  • AI Scientist
  • PhD in Computer Science/Artificial Intelligence/Machine Learning or related technical fields
  • 3+ years of work experience post-PhD in an industrial setting or equivalent academic post-doctoral experience
  • Track record of AI Innovation demonstrated through publications in Artificial Intelligence/Machine Learning or projects applying them to interdisciplinary fields
  • Peer reviewed published research in developing AI methods (example in ICLR, NeurIPS, ICML, Nature, Science, Cell etc.)
  • Experienced in PyTorch, training and inference of large models on GPUs
  • Hands-on experience with foundation models or large-scale self-supervised learning (e.g., transformers, variational autoencoders)
  • Strong expertise in single-cell data analysis, particularly perturb-seq
  • Familiarity with multi-omics integration and multi-modal foundation models
  • Experience in working at the interface of AI and Biology

Responsibilities

  • (Not explicitly listed in the job description; primarily qualifications-focused for recruitment at NeurIPS 2025)

Skills

Python
Deep Learning
Neural Networks
Machine Learning
AI Model Deployment
Bioinformatics
Computational Chemistry

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI